

# Sample: LSI 2025 Emerging *Innovators Report*

Proprietary LSI Event Data and Compass Insights on 500+ Medtech Innovators



## LETTER FROM THE EDITORS

Dear Readers,

Innovation, capital, and partnering are what move medtech forward. That intersection is where LSI lives. Every year, founders, investors, strategics, bankers, and advisors come together at our global LSI summits to do one thing: find and fund the technologies that will define the future of healthcare.

This 2025 Emerging Innovators Report is the annual snapshot of that ecosystem.

In 2025, we selected over 500 emerging companies to take the stage across our three LSI summits. Together, these innovators have already raised more than \$10.58B in capital, and in calendar year 2025 alone they were in the market for an additional \$6.995B in follow-on rounds. Since stepping into the LSI spotlight, they have driven hundreds of new financings, M&A transactions, and strategic partnerships.

This report is designed to give you a single, reliable view of that dealflow.

The companies featured here span 36 countries, with 274 based in the United States, 147 across Europe, and more than 99 from the rest of the world. They cover the full spectrum of early-stage medtech: over half are in pre-seed, seed, or Series A, with another 140+ at Series B and C and a meaningful cohort entering later-stage scale-up.

Their technologies tackle the toughest problems in healthcare, from nearly eighty companies focused on neurological disease, to a similar number targeting cardiovascular conditions, more than eighty in orthopedics, over thirty in urology, and close to sixty explicitly leveraging AI to reimagine diagnostics, interventions, and care delivery.

Our goal with this report is simple: to be the annual, single source of truth for the most important early-stage medtech companies in the world. If you are an investor looking for your next breakout opportunity, a multinational searching for future acquisition targets, an investment bank supporting the next wave of IPOs, or a best-in-class service partner seeking to build tomorrow's category leaders, this report is built for you. Every company profiled here isn't just on our radar: they are already reshaping the care we experience today.

What makes this work unique is not just the list of companies, but the ecosystem and data behind it. The insights in this report are powered by Compass, LSI's AI-driven private market insights platform. Compass connects what happens on our stages and in our partnering rooms with a continuously-updated view of private market activity, investment decisions, competitive landscapes, and the broader trends shaping global medtech. What you see in these pages is broad by design. For deeper analysis on any company, its peers, or its market, Compass is your gateway.

We are committed to publishing the Emerging Innovators Report once per year as our "state of the union" for early-stage medical technologies. Our belief is that any early-stage medtech company of real consequence will either already appear in these pages or soon will. If you stay close to this report, its supporting content, and the LSI community that powers it, you will not be far from the next wave of opportunity.

We hope you find this report useful, and we look forward to supporting you and your organization as you build the next generation of breakthrough medtech businesses.

Thanks for being part of this community.

All the best,



Scott Pantel & Henry Peck  
*Editors-in-Chief*




## BUILT WITH COMPASS

The LSI 2025 Emerging Innovators Report covers every startup company that presented at LSI summits in 2025, with the expert insights and proprietary intelligence that power our Compass AI platform. Inside are company profiles, funding activity, executive summaries, and curated analyst commentary, all drawn from the same internal datasets used by the LSI Market Intelligence team. The result is a single, structured view of the year's most significant early-stage and growth-stage innovators, presented in a format built to support research, sourcing, and strategic planning.

Users can now generate reports inside Compass using AI Agents, which turn natural-language prompts into tailored analyses, competitive landscapes, or investor-ready summaries. The AI Agents automatically pull from Compass datasets that cover companies, deal activity, market forecasts, and editorial content, in concert with trusted external resources to strengthen context. Whether you need diligence briefs, market maps, or presentation-ready insight packs, Compass AI Agents allow you to create polished reports on demand, fully aligned to your workflow.

## Navigate medtech with AI insights and *data you can trust*

Compass is the medtech-specific AI research platform, built by medtech analysts for the medtech operators, investors, and strategic executives who need to move quickly and make confident decisions.



## Private market data, vetted research, and curated content that *no one else has*

Discover emerging companies, track industry deals, and analyze market landscapes with AI that synthesizes millions of data points from LSI's proprietary datasets, built on decades of primary research and direct company relationships



## AI agents that understand *medtech and your workflows*

Compass's intelligent agents turns natural-language questions into actionable insights, automatically sourcing from across LSI's entire database, visualizing trends, and drafting reports.






TABLE OF INNOVATORS

2Pi-Sigma	05	CardiaCare	95	H2 Global Group	185
3Aware	06	CARDIAWAVE	96	Hadleigh Health Technologies	186
4D Medicine	07	Caretaker Medical	97	Happitech	187
ABILITY Neurotech	08	CDX Medical Technologies	98	HapticHeart	188
ABS Technologies	09	Cellviva	99	Haventure	189
Accure Acne	10	Centerline Biomedical	100	Healing Innovations	190
Aclarion	11	Centese	101	HealthMosaic	191
Acoustic Wave Cell Therapy	12	CerebraAI	102	Heart Biotech	192
ACT Medical	13	Cergenx	103	Helico Technologies	193
AcuamarkDX	14	Cern	104	HemaSense	194
Adaptyx Biosciences	15	Ceroflo	105	HEMEO	195
Additive Implants	16	Charco Neurotech	106	HEPTA Medical	196
AdjuCor	17	Circular Genomics	107	Heteron Biotechnologies	197
Adtec Healthcare	18	CivaTech Oncology	108	Hy2Care	198
Aevice Health	19	Clairity	109	Hyalex Orthopaedics	199
AGADA Medical	20	Claro Surgical	110	Image Navigation	200
Agilis Robotics	21	Clinicians Touch Allyve	111	Imagine Devices	201
Agitated Solutions (ASI)	22	Coagulation Sciences	112	IMMA Health	202
AiCESS	23	Cognito Therapeutics	113	ImpediMed	203
AimSense	24	Conform Medical	114	Implant Preservation Devices	204
Aim Medical Robotics	25	ConnCons	115	Implican	205
AKT Health	26	Coramaze Technologies	116	IMRA Surgical	206
Akura Medical	27	CorInnova	117	INEX Innovate	207
Alara Med	28	CorNeat Vision	118	InFlo Medical	208
AliveCor	29	CorTec	119	Informed Surgical	209
Allheartz	30	Corticale	120	Inhibit Coatings	210
Altach Biomedical	31	CorVista Health	121	InkSpace Imaging	211
Altoida	32	CorWave	122	INNITIUS	212
Altra	33	Cranial Devices	123	Innotive Diagnostics	213
Amber Implants	34	CranioSense	124	Innova Vascular	214
Amplifi Vascular	35	CraniUS	125	InnovHeart	215
Amsel Medical	36	Cresilon	126	Inossia AB	216
Anaconda BioMed	37	Crimson Scientific	127	Integrated Medical Sensors	217
Ananda Devices	38	Crocevia Medical	128	Interlinked	218
Anaut-Surg	39	Cryosa	129	Intravascular Imaging Inc. (i3)	219
ANEUVO	40	CustomSurg	130	Intressa Vascular	220
AngioInsight	41	Cx Precision Medicine	131	Invenio Imaging	221
Anivia Medical	42	CygnusMed	132	InVera Medical	222
Annaida Technologies	43	DeepSight Technology	133	IQ Urology	223
Aposture Surgical	44	Del MedTech	134	IQ Endoscopes	224
Append Medical	45	Delphinus Medical Technologies	135	IRIS XR	225
Aqua Medical	46	DH Medical	136	Jackson Medical	226
ARC Medical	47	Dialybrid	137	Joint Preservation Innovations	227
Arcuro Medical	48	Diligent Robotics	138	Juniper Biomedical	228
Arsenal Medical	49	Dilon Diagnostics	139	Kai.ai	229
Art Medical	50	Distalmotion	140	Kallisio	230
Arterica	51	Dxcover	141	Kneevoice	231
Aruna Revolution	52	EBAMed	142	Lazzaro Medical	232
ATDev	53	Ebenbuild	143	LearUp Systems	233
Athena DiaX	54	eCential Robotics	144	Lem Surgical	234
Atia Vision	55	EchoIQ	145	Lemonex	235
Atmo Biosciences	56	Echopoint Medical	146	Leucadia Therapeutics	236
ATRO Medical	57	Eclipse Regeneration	147	Life Seal Vascular	237
Aulisa Medical	58	EerDx	148	Limis	238
Autonomix Medical	59	EFA Technologies	149	Linio Biotech	239
Avatar Medical	60	Efemoral Medical	150	Linshom Medical	240
Aveda Health	61	Egg Medical	152	Lionheart Health	241
Avertix Medical	62	ElectraDx	152	Liposphere	242
AvobisBio	63	Elucid	153	LIQID Medical	243
Avvio Medical	64	EMBioSys	154	Liquet Medical	244
Axena Health	65	Emboline	155	LiveMetric	245
Axoft	66	Emovi	156	Locate Bio	246
AyrFlo	67	Endeavor Orthopedics	157	Lucida Medical	247
Azalea Vision	68	Endolumik	158	Lumicell	248
Bayou Surgical	69	EndoShunt Medical	159	Lumipen Pro	249
Berlin Heals	70	EP Solutions	160	Lupin Dental	250
Bimini Healthtech	71	Epion Therapeutics	161	LuSeed Vascular	251
BioAro	72	Epitel	162	Maculaser	252
Biobot Surgical	73	EpiWatch	163	Madison Scientific (MadSci)	253
BIOCAPTIVA	74	Exero Medical	164	magAssist	254
Biorithm	75	Fastnalign	165	Magellan Biomedical	255
Blend	76	Fibioseq Medical	166	Magloy Tech	256
Bloom Therapeutics	77	Field Orthopaedics	167	Magnendo	257
BMD	78	Finally Quiet	168	MALCOVA	258
BMI OrganBank	79	FlexDex Surgical	169	Maternal Newborn Health Innovations	259
Brain Dynamics	80	Flomics Biotech	170	MaxQ Medical	260
brain4care	81	Flow Medical	171	May Health	261
BrainCapture	82	Fluid Biomed	172	Medical Inventi	262
BrainSpace	83	FoxEyes	173	Medulla Pro	263
Brattea	84	Fundamental XR	174	Meduloc	264
Breath Diagnostics	85	Galena Innovations	175	Medyria	265
Bryan Therapeutics	86	GID BIO	176	Meracle	266
Buck Surgical	87	GlucoModicum	177	Methinks AI	267
Butterfly Medical	88	GORYO Chemical	178	Micro Interventional Devices	268
Byonyks	89	GraMedica	179	MicroSteer	269
Caira Surgical	90	GT Medical Technologies	180	Microsure	270
CairnSurgical	91	Guard Medical	181	MIMOSA Diagnostics	271
Calla Lily Clinical Care	92	GuideAI Health	182	MindTrace	272
Cannulight	93	Gulf Medical Technologies	183	Mirai Medical	273
CAPS Medical	94	Gyder Surgical	184	Modulim	274



TABLE OF INNOVATORS

Moximed	275	Proluma Medical	365	ThinkSono	455
MYO1	276	Protembis	366	Thorasys Thoracic Medical Systems	456
MyBiometry	277	Proton Intelligence	367	Thubrikar Aortic Valve	457
Myochron	278	PulmoBioMed	368	TibaRay	458
Nalu Medical	279	PURMX Therapeutics	369	Tioga Cardiovascular	459
Nano4Imaging	280	Quantanosis	370	Titanium Textiles	460
Nanochon	281	QuantiLight	371	Toku Eyes	461
Nanoflex Robotics	282	QuantumTX	372	TomoWave	462
Nanostics	283	Qureator	373	Total Flow Medical	463
Nanovision Technology	284	Radialis Medical	374	Trace Orthopedics	464
Navigate Maternity	285	RADuxtion	375	Tresquare Technologies	465
Navigation Sciences	286	Reach Neuro	376	TripleMed	466
Neocor	287	Reach Orthopaedic	377	Trisail Medical	467
NeoPredics	288	Reborn Medical	378	TYBR Health	468
NeuraSignal	289	RebrAln	379	UltraSight	469
Neuroelectrics	290	Refined Laser Systems	380	UNEEG Medical	470
Neuronoff	291	ReGeltec	381	Uplyft Health	471
Neurosom	292	Rekovar	382	URO-1	472
NEVENT	293	Reprieve Cardiovascular	383	Valeb	473
New Phase	294	Resolve Stroke	384	Vantis Vascular	474
Newmanbrain	295	RespirAI	385	Vartid	475
Newronika	296	Restera	386	Vascular Perfusion Solutions	476
Newrotex	297	Retia Medical	387	VeinTech	477
NewUro	298	RetiSpec	388	Vektor Medical	478
Nia Therapeutics	299	RevBio	389	Vena Vitals	479
NICE Surgical	300	Reveal Dx	390	Venock Medical	480
NIMBLE Diagnostics	301	Revision Implant	391	Vensica Medical	481
Nina Medical	302	Riff Medical	392	Venstra Medical	482
Nitinotes	303	Rivanna Medical	393	Versono Medical	483
Njord Medtech	304	Rob Surgical Systems	394	Vessl Prosthetics	484
Noah Labs	305	ROB'E	395	Vesteck	485
Noninvasix	306	Roivios	396	Vibrato Medical	486
Noscendo	307	Rosalind Dx	397	ViCentra	487
Nostics	308	Runway Healthcare	398	VirtaMed	488
Nousq	309	Rx Bandz	399	VISIE	489
Novadip Biosciences	310	SamanTree Medical	400	Visura Technologies	490
NovApproach Spine	311	Sana Health	401	Vitazi.ai	491
NovaResp Technologies	312	Scalpel AI	402	VitIs	492
NovaScan	313	ScienceForBrain	403	VitVio	493
Novian Health	314	Scout Health	404	Vivid Dx	494
Novuson Surgical	315	SDIP Innovations	405	Vivo Surgical	495
Noxilizer	316	Seerling	406	Volta Medical	496
NunaBio	317	Sensars	407	Vomaris	497
Nuri Braintech	318	Sensome	408	Vortex Imaging	498
Nutromics	319	Sequana Medical	409	Wave Neuroscience	499
Nyxoah	320	SERDA Therapeutics	410	Wearable Artificial Organs	500
NZ Technologies	321	Serox	411	WearOptimo	501
Omniscient Neurotechnology	322	ShakeIQ	412	Wellumio	502
OncoRes Medical	323	Shape Memory Medical	413	Wellvii	503
Onera Health	324	Simplex Quantum	414	Wellysis	504
OneStep	325	Sirica Therapeutics	415	WhiteSwell	505
Optheras	326	SitnStand	416	WISE	506
Optina	327	Skope	417	Xeltis	507
Orion Innovations	328	Sleep Mechanics	418	Xenocor	508
Orpyx Medical	329	Solaris Endovascular	419	XeroThera	509
Orthobond	330	Solenic Medical	420	XN Health	510
Orthonika	331	Somavac	421	Xpan	511
OrthoPreserve	332	Sonic Incytes Medical	422	XLabs	512
Ossiform	333	Sonion HealthTech	423	XRMedix	513
Osteal Therapeutics	334	Sonofii	424	Yaqrit	514
Osteoboost	335	Soterya	425	Zedsen	515
OsteoCure Therapeutics	336	Sparta Biomedical	426	Zepto Life Technology	516
OstomySecure	337	Spatial Surgical	427	Zeta Diagnostics	517
Panda Surgical	338	SpectraWAVE	428	ZKR Orthopedics	518
Paradromics	339	SpinaFX	429	ZuriMed Technologies	519
PatenSee	340	Spinally Medical	430	ZygoFix	520
PAVmed	341	SpinePoint	431		
PEDRA Technology	342	Spiro Robotics	432		
Peerbridge Health	343	StarTric	433		
Percusense	344	STENTIT	434		
Percy	345	Stimit	435		
Perfuze	346	Surfix Diagnostics	436		
Perimeter Medical Imaging	347	SurgiBox	437		
Peytant Solutions	348	Sutra Medical	438		
PharmaJet	349	SyMap Medical	439		
PharmaSens	350	Synergia Medical	440		
PhotoniCare	351	Synova Life Sciences	441		
PhotoPharmics	352	SynSeer Technologies	442		
Pixee Medical	353	Tau Medical	443		
Planatome	354	Taurus Vascular	444		
Plexãã	355	TECHFIT Digital Surgery	445		
Polarean	356	Telesair	446		
Polaris AR	357	Tempo Therapeutics	447		
Portal Instruments	358	Tendonplus Medical	448		
Powerful Medical	359	Tensive	449		
Prana Surgical	360	Tensor Surgical	450		
Precision Cardiovascular	361	Tetrous	451		
Precisis	362	The Insides Company	452		
PreciX	363	Theradaptive	453		
Pretika	364	THINK Surgical	454		



COMPASS DATA



ABILITY  
Neurotech

CLINICAL (PRE-REVENUE)

NEURO

📅 Year Founded	2025
👤 Employees	16
👤 Key Executive	Craig Cook craig.cook@abilityneuro.com
💰 Raised to Date	Undisclosed
💰 Currently Raising (2025)	\$40,000,000
🏢 Commercial Status	Clinical (Pre-Revenue)
📈 Major Milestones	FDA Breakthrough Device Designation, First human trials
🎯 Target Markets	Neuro
📍 Location	Switzerland
🌐 Company Website	abilityneuro.com



COMPASS INSIGHTS

Pioneering Neurotechnology  
with BCI Tech for  
Severe Paralysis

Ability Neurotech is developing a next-generation brain computer interface (BCI) to restore communication and motor control in patients with severe neurological conditions, including ALS, brainstem stroke, cortical stroke, and neurodegenerative diseases. The company originated at the Wyss Center for Bio and Neuroengineering in Geneva, where the founding team, led by Professor John Donoghue, spent seven years advancing the platform. More than \$50M has been invested so far, and the program was spun out as an independent company in early 2024. Ability plans to begin its first in human clinical trial in Europe later this year, starting with ALS patients.

The platform's core innovation is its optical data transmission system, which the company positions as a breakthrough compared with radio frequency and Bluetooth based approaches. The implant captures and transmits raw neural data at bandwidths of about 50 mbps, which Ability reports is 25-50x greater than competing BCI systems. A laser based optical link sends neural signals from electrodes in the brain through the skull to an external wearable, allowing access to fuller, higher fidelity data that may support richer biomarkers and more advanced AI decoding models for restoring motor and communication function.

The hardware consists of a permanently implanted, batteryless device that sits flush with the skull, with electrodes directly interfacing with the cortex. The implant is under 5 mm thick and avoids the need for external pedestals, chest mounted components, or repeat surgeries for battery replacement. A magnetic external wearable receives the optical transmissions, creating what the company calls a window to the brain. This design aims to reduce invasiveness and aesthetic barriers, and improves comfort and long-term safety. Preclinical large animal studies have shown safety, implantability, and functional performance, supporting regulatory clearance to move into human testing.

Ability estimates that its first generation system will address a \$1B market in ALS, brainstem stroke, and spinal cord injury, with a second generation expanding to cortical stroke and neurodegenerative diseases for a total potential market of \$50B. Broader industry forecasts, including a recent Morgan Stanley report, project a \$400B BCI opportunity in the United States. Ability has raised \$7M in initial funding and is now pursuing a \$40M Series A, with a lead investor already committed. With experienced leadership and first in human studies approaching, the company positions itself as one of the few globally advancing a complete, fully implantable BCI platform.



COMPASS DATA



Bayou Surgical

COMMERCIAL WITH REVENUE LESS THAN \$5M

GENERAL SURGERY    OB/GYN

Year Founded	2018
Employees	7
Key Executive	Sharad Joshi sharad.joshi@bayousurgical.com
Raised to Date	\$8,250,000
Currently Raising (2025)	\$10,000,000
Commercial Status	Commercial with revenue LESS than \$5M
Major Milestones	FDA Clearance 510(k) class II, First in man robotic procedures and laparoscopic procedures
Target Markets	General Surgery, OB/GYN
Location	United States
Company Website	bayousurgical.com



COMPASS INSIGHTS

Hands-Free Scope Cleaning System for Minimally Invasive Surgery

Bayou Surgical addresses a persistent challenge in minimally invasive surgery: surgeons frequently lose visibility when laparoscopes fog or become soiled with blood, fat, and tissue. This forces repeated scope removal, wiping, and reinsertion during roughly 17.2 million procedures annually, leaving surgeons “blind” 37% of the time in laparoscopy and 53% in robotics. These interruptions add \$800–\$900 in soft and hard costs per case. Bayou’s troCarWash is an FDA-cleared trocar with built-in, hands-free scope cleaning. Surgeons slightly retract the scope, a light sensor triggers, and a 0.3-second pulse of dry CO<sub>2</sub> with a proprietary surfactant and saline clears fog and debris without removing the scope or disengaging robotic instruments.

The system integrates seamlessly into standard workflows. It requires no add-on sheath, maintains current port sizes, and works with common scope dimensions. Sold on a razor/razor-blade model, it features a reusable control unit plus a single-use disposable trocar and tubing set. Bench and clinical studies across general surgery, thoracic, and OB-GYN procedures show rapid restoration of visibility, reduced scope exchanges, and improved safety when bleeding obscures the lens. Compared to alternatives that require scope removal or oversized ports, troCarWash cleans in place and preserves port size, lowering hernia risk. The company holds 24+ issued or pending patents and ensures compatibility with robotic and AI-assisted workflows.

Commercial strategy targets high-volume MIS centers with direct sales, supported by distributors in lower-density markets. Led by CEO Sherrod Joshi with 35 years of medtech experience, the team includes surgical innovators with multiple successful exits. U.S. rollout of the 10 mm device is underway, with a 5 mm version and robotic-specific variants in development. Early economics suggest that time savings and fewer scope exchanges can generate significant operating room efficiency and throughput improvements. Comparable sales, such as a competitor acquisition by Medtronic at approximately \$115M, highlight the strategic value of the market.

Bayou is raising a \$10M Series B to expand commercial adoption of the 10 mm device, launch the 5 mm line, develop robotic-specific SKUs, and continue IP development. With an FDA-cleared, workflow-preserving technology that addresses a costly and pervasive problem in minimally invasive surgery, Bayou Surgical is positioned to scale rapidly, improving surgical efficiency, patient safety, and hospital costs.



COMPASS DATA



Caira Surgical

PRE-CLINICAL (PRE-REVENUE)

ORTHOPEDIC

📅 Year Founded	2019
👤 Employees	8
👤 Key Executive	Jon Greenwald jgreenwald@cairasurgical.com
💰 Raised to Date	\$15,300,000
💰 Currently Raising (2025)	\$10,000,000
🏢 Commercial Status	Pre-Clinical (Pre-Revenue)
📈 Major Milestones	In 2H-24 the company reached an early evaluation agreement with a leading strategic
🎯 Target Markets	Orthopedic
📍 Location	United States
🌐 Company Website	cairasurgical.com



COMPASS INSIGHTS

Radar-Based Tracking for Joint Replacement

CAIRA Surgical is redefining orthopedic robotics by removing the long-standing barriers that have limited adoption. Although more than 3.5 million knee replacements are expected annually in the U.S. by 2030, only 17% use robotic assistance because today’s optical tracking systems are costly, cumbersome, and dependent on invasive pins, extra incisions, and bulky line-of-sight cameras. CAIRA’s mission is to make robotic-assisted surgery simpler, safer, and more cost-effective.

At the core of CAIRA's platform is radar-based tracking, a breakthrough alternative to optical systems. Compact radar “beacons” fit entirely within the incision, require only one bone screw, can be removed and replaced during surgery, and never lose calibration. A small touchscreen console with six radar sensors operates in the sterile field and eliminates line-of-sight issues, reducing workflow disruptions, improving ergonomics, and cutting capital and per-case costs by up to 75%.

The platform integrates radar tracking, AI-driven intraoperative planning, and rapid anatomical registration. A handheld scanner maps patient anatomy in 90 seconds, which is far faster than conventional probing, and clinical simulations show 11–25 minutes saved per procedure, translating to roughly \$2,500 in OR savings. The system also reduces pin-site complications, avoids optical-tracking interruptions, and shortens the learning curve for new users.

CAIRA is initially targeting the \$13B total knee replacement market before expanding into hip and spine. Its open architecture works with any implant system, unlike existing manufacturer-tied robots. A limited release is planned for 2026 with 23 surgeons across 13 centers, supported by a 510(k) pathway with multiple predicates and four granted patents. Backed by an experienced orthopedic leadership team, CAIRA is raising \$10M in Series A funding to complete FDA clearance and launch the platform, positioning the company for strong commercial uptake and future strategic acquisition.



COMPASS DATA



DeepSight  
Technology

CLINICAL WITH REVENUE LESS THAN \$5M  
INTERVENTIONAL RADIOLOGY

📅 Year Founded	2019
👤 Employees	61
👤 Key Executive	Diku Mandavia dmandavia@deepsight.com
💰 Raised to Date	\$60,000,000
💰 Currently Raising (2025)	\$50,000,000
🏢 Commercial Status	Clinical with revenue LESS than \$5M
🏆 Major Milestones	FDA 510(k) clearance for the NeedleVue™ platform and first human scanning expected Q3 '2025
🎯 Target Markets	Interventional Radiology
📍 Location	United States
🌐 Company Website	deepsight.com



COMPASS INSIGHTS

Smart Needle  
Ultrasound Guidance for  
Interventional Precision

DeepSight Technologies, led by Chief Medical Officer Dr. Diku Mandavia, is modernizing interventional medicine by reinventing one of its most basic tools: the needle. While minimally invasive procedures have advanced dramatically, needle design has barely changed for more than a century, creating persistent challenges for proceduralists who rely on precise, real-time visualization. DeepSight has developed a new class of intelligent instruments equipped with breakthrough ultrasound sensing technology that provides trajectory guidance, real-time tip tracking, and the first anatomical ultrasound view directly from the needle tip.

The company's proprietary 50-micron sensor is smaller than a human hair and represents a major leap in procedural imaging. It is inert, non-electrical, omnidirectional, and safe for use in high-heat or cryothermal environments. When integrated into a standard needle, the sensor projects a bright marker on the ultrasound screen, revealing the exact location of the needle tip in real time. Clinicians can now see both the needle pathway and surrounding anatomy simultaneously, greatly improving accuracy, safety, and confidence during complex interventions.

DeepSight's platform integrates advanced imaging, smart hardware, and AI-assisted software into a single system. The company offers its own ultrasound unit and a bolt-on solution compatible with more than 100,000 installed hospital systems in the United States. Its smart stylets and software suite enable guided navigation, workflow support, and remote oversight. DeepSight also plans partnerships with manufacturers of catheters, ablation tools, and implantable devices to create integrated, sensor-enabled procedural ecosystems. The company's intellectual property position includes more than 100 granted or pending patents and multiple exclusive licenses.

The addressable market spans ultrasound, interventional imaging, and the wider surgical instruments category. DeepSight will launch in abdominal biopsy and then expand into tumor and cardiac ablations, structural heart and vascular access procedures, spinal and pain interventions, and targeted drug delivery. Early physician feedback points to meaningful reductions in error rates, faster procedures, and broader access to advanced image-guided techniques. With its first OEM customer secured, FDA submission complete, and commercial launch planned for this year, DeepSight Technologies is positioned to set a new benchmark for precision and safety in interventional care.













COMPASS DATA



*EBAMed*

CLINICAL (PRE-REVENUE)

CARDIOVASCULAR

 Year Founded	2018
 Employees	15
 Key Executive	Marina Izzo marina.izzo@eba-med.com
 Raised to Date	\$21,000,000
 Currently Raising (2025)	Undisclosed
 Commercial Status	Clinical (Pre-Revenue)
 Major Milestones	Design Freeze: the CardioKit is now ready for manufacturing preparation and regulatory testing
 Target Markets	Cardiovascular
 Location	Switzerland
 Company Website	eba-med.com



COMPASS INSIGHTS

# Non-Invasive Radiation Therapy for Cardiac Arrhythmias

EBAMed, based in Geneva, is developing a novel image-guided radiation therapy system to treat cardiac arrhythmias without invasive procedures. Its platform, CardioKit, is an add-on guidance system for radiotherapy devices that enables precise stereotactic radioablation of arrhythmic cardiac tissue. Using proprietary ultrasound imaging and artificial intelligence, the system synchronizes radiation delivery with both cardiac and respiratory motion. The technology aims to provide life-saving treatment for ventricular tachycardia patients who cannot undergo traditional catheter-based ablation, reducing procedural risk and expanding access.

Current ventricular tachycardia ablations are complex, risky, and lengthy. Catheter procedures carry roughly a 5% 30-day mortality rate and can produce suboptimal outcomes due to the heart’s constant motion. EBAMed’s non-invasive approach leverages existing radiotherapy equipment to deliver focused beams externally, shortening procedures from four to six hours to under one hour. By tracking cardiac and respiratory motion, CardioKit maintains target precision, overcoming a key limitation of standard stereotactic ablation methods.

Over the past 18 months, EBAMed has completed preclinical studies with Massachusetts General Hospital and the University of Pennsylvania, showing that dual gating reduces treated tissue volume by 37% while achieving full-thickness ventricular lesions. The AI algorithm has been validated using imaging data from 24 patients, supporting readiness for first-in-human trials. The company has completed design freeze and is initiating an initial clinical feasibility and safety study as part of a U.S. regulatory pathway, aiming for a pivotal study with primary endpoints by late 2026.

EBAMed holds a robust intellectual property portfolio, including a licensed Mayo Clinic patent for proton therapy applications and internally developed patents for motion tracking, echo-free imaging, and beam latency compensation. Led by CEO Marina Izzo, former head of electrophysiology at St. Jude Medical, the team combines expertise in cardiology, radiotherapy, and device regulation. With early clinical validation, academic collaboration, and regulatory readiness, EBAMed is positioned to redefine non-invasive cardiac ablation, making complex electrophysiologic interventions safer, faster, and more widely accessible.



Full Report Available For Purchase

# You've Just Seen 5 Pages, *Get All 500+*

Access full profiles, funding data, milestones, markets, and analyst insights on every innovator in this report.